Wordt geladen...
Golimumab pharmacokinetics in ulcerative colitis: a literature review
Golimumab (GLM) is the latest anti-tumor necrosis factor (TNF) that gained its marketing license. Thanks to the PURSUIT induction and maintenance trials, it was approved for the treatment of ulcerative colitis (UC) in 2013. The other anti-TNF drugs available are infliximab and adalimumab. These two...
Bewaard in:
| Gepubliceerd in: | Therap Adv Gastroenterol |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
SAGE Publications
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5330616/ https://ncbi.nlm.nih.gov/pubmed/28286562 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16676194 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|